Risk factors for CMV infection within 100 days posttransplantation in patients with acute leukemia

被引:2
作者
Chen, Juan [1 ]
Pang, Aiming [1 ]
Zhao, Yuanqi [1 ]
Liu, Li [1 ]
Ma, Runzhi [1 ]
Wei, Jialin [1 ]
Chen, Xin [1 ]
He, Yi [1 ]
Yang, Donglin [1 ]
Zhang, Rongli [1 ]
Zhai, Weihua [1 ]
Ma, Qiaoling [1 ]
Jiang, Erlie [1 ]
Han, Mingzhe [1 ]
Zhou, Jiaxi [1 ]
Feng, Sizhou [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Natl Clin Res Ctr Blood Dis, Haihe Lab Cell Ecosyst,State Key Lab Expt Hematol, Tianjin 300020, Peoples R China
来源
BLOOD SCIENCE | 2022年 / 4卷 / 03期
关键词
Acute leukemia; Allogeneic hematopoietic stem cell transplantation; Cytomegalovirus; Risk factors; Relapse; CYTOMEGALOVIRUS REACTIVATION; TRANSPLANTATION; RECOVERY; CELLS; ASSAY;
D O I
10.1097/BS9.0000000000000121
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To investigate the risk factors for cytomegalovirus (CMV) infection within 100 days and the relationship between early CMV infection and 1-year relapse for patients with acute leukemia following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Methods: Three hundred fifty-nine patients with acute leukemia who received allo-HSCT at our center between January 2015 and January 2020 were retrospectively reviewed. Results: Of 359 patients, 48.19% (173) patients experienced CMV infection within 100 days posttransplantation. In univariate and multivariate logistic analysis, haploidentical-related donor (HRD) (P < 0.001; odds ratio [OR], 5.542; 95% confidence interval [CI], 3.186-9.639), and ratio of CD3(+)CD8(+) cells in lymphocytes <14.825% (P < 0.001; OR, 3.005; 95% CI, 1.712-5.275) were identified as 2 independent risk factors. One-year relapse rate (RR) between the CMV infection group and the non-CMV infection group was not statistically significant (18.5% vs 19.9%, P = 0.688). When we divided the total cohort into AML, ALL, and MAL subgroups, there were no significant differences as well (P = 0.138; P = 0.588; P = 0.117; respectively). Conclusion: In conclusion, donor type (HRD) and the insufficient recovery of CD3(+)CD8(+) cells were independent risk factors for CMV infection within 100 days posttransplantation in patients with acute leukemia. CMV infection within 100 days did not influence the incidence of relapse in 1 year for patients with acute leukemia.
引用
收藏
页码:164 / 169
页数:6
相关论文
共 26 条
  • [1] Scoring system for clinically significant CMV infection in seropositive recipients following allogenic hematopoietic cell transplant: an SFGM-TC study
    Beauvais, David
    Drumez, Elodie
    Blaise, Didier
    de Latour, Regis Peffault
    Forcade, Edouard
    Ceballos, Patrice
    Uyttebroeck, Anne
    Labussiere, Helene
    Nguyen, Stephanie
    Bourhis, Jean-Henri
    Chevallier, Patrice
    Thiebaut, Anne
    Poir, Xavier
    Maury, Sebastien
    Deconinck, Eric
    Cluzeau, Thomas
    Brissot, Eolia
    Huynh, Anne
    Rubio, Marie-Therese
    Duhamel, Alain
    Yakoub-Agha, Ibrahim
    [J]. BONE MARROW TRANSPLANTATION, 2021, 56 (06) : 1305 - 1315
  • [2] Deep functional immunophenotyping predicts risk of cytomegalovirus reactivation after hematopoietic cell transplantation
    Camargo, Jose F.
    Wieder, Eric D.
    Kimble, Erik
    Benjamin, Cara L.
    Kolonias, Despina S.
    Kwon, Deukwoo
    Chen, Xi Steven
    Komanduri, Krishna, V
    [J]. BLOOD, 2019, 133 (08) : 867 - 877
  • [3] Camargo Jose F, 2017, Hematol Oncol Stem Cell Ther, V10, P233, DOI 10.1016/j.hemonc.2017.05.001
  • [4] Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study
    Chemaly, Roy F.
    El Haddad, Lynn
    Winston, Drew J.
    Rowley, Scott D.
    Mulane, Kathleen M.
    Chandrasekar, Pranatharthi
    Avery, Robin K.
    Hari, Parameswaran
    Peggs, Karl S.
    Kumar, Deepali
    Nath, Rajneesh
    Ljungman, Per
    Mossad, Sherif B.
    Dadwal, Sanjeet S.
    Blanchard, Ted
    Shah, Dimpy P.
    Jiang, Ying
    Ariza-Heredia, Ella
    [J]. CLINICAL INFECTIOUS DISEASES, 2020, 71 (09) : 2365 - 2374
  • [5] How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation
    Einsele, Hermann
    Ljungman, Per
    Boeckh, Michael
    [J]. BLOOD, 2020, 135 (19) : 1619 - 1629
  • [6] How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients
    El Chaer, Firas
    Shah, Dimpy P.
    Chemaly, Roy F.
    [J]. BLOOD, 2016, 128 (23) : 2624 - 2636
  • [7] Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients
    Elmaagacli, Ahmet H.
    Steckel, Nina K.
    Koldehoff, Michael
    Hegerfeldt, Yael
    Trenschel, Rudolf
    Ditschkowski, Markus
    Christoph, Sandra
    Gromke, Tanja
    Kordelas, Lambros
    Ottinger, Hellmut D.
    Ross, Rudolf S.
    Horn, Peter A.
    Schnittger, Susanne
    Beelen, Dietrich W.
    [J]. BLOOD, 2011, 118 (05) : 1402 - 1412
  • [8] Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function
    Foley, Bree
    Cooley, Sarah
    Verneris, Michael R.
    Pitt, Michelle
    Curtsinger, Julie
    Luo, Xianghua
    Lopez-Verges, Sandra
    Lanier, Lewis L.
    Weisdorf, Daniel
    Miller, Jeffrey S.
    [J]. BLOOD, 2012, 119 (11) : 2665 - 2674
  • [9] CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia
    Green, Margaret L.
    Leisenring, Wendy M.
    Xie, Hu
    Walter, Roland B.
    Mielcarek, Marco
    Sandmaier, Brenda M.
    Riddell, Stanley R.
    Boeckh, Michael
    [J]. BLOOD, 2013, 122 (07) : 1316 - 1324
  • [10] Early CMV replication and subsequent chronic GVHD have a significant anti-leukemic effect after allogeneic HSCT in acute myeloid leukemia
    Jang, Ji Eun
    Kim, Soo Jeong
    Cheong, June-Won
    Hyun, Shin Young
    Kim, Yun Deok
    Kim, Yu Ri
    Kim, Jin Seok
    Min, Yoo Hong
    [J]. ANNALS OF HEMATOLOGY, 2015, 94 (02) : 275 - 282